Page 6 - உலகளாவிய தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat.

United statesUnited kingdomMartyj duvallAnders martinRolf gulliksenKlaas bakkerLinda holmstrJakob lindbergAmerican society of hematologyUniversity of rotterdamDrug administrationGlobal head of corporate communicationsNasdaq stockholmChief executive officerHazard ratioOverall response rate

Oncopeptides AB: Invitation to presentation of the Q1 2021 results

STOCKHOLM, May 20, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological

United statesMartyj duvallRolf gulliksenLinda holmstrGlobal head of corporate communicationsNasdaq stockholmOncopeptide leadershipCorporate communicationsInvestor relationsMid capஒன்றுபட்டது மாநிலங்களில்உலகளாவிய தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம்பெருநிறுவன தகவல்தொடர்புகள்முதலீட்டாளர் உறவுகள்நடுவில் தொப்பி

Sun Country Airlines Holdings, Inc Announces Pricing of Upsized Secondary Public Offering of Common Stock

Sun Country Airlines Holdings, Inc Announces Pricing of Upsized Secondary Public Offering of Common Stock
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkChris allenJoanna rosePeter mintzbergJessica wheelerMorgan stanleyBroadridge financial solutionsBarclays capital incGlobal head of corporate communicationsDeutsche bank securitiesSun country airlines holdings incProspectus departmentMorgan stanley coTribal marketsSun country airline registration statement on form

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology News provided by Share this article Share this article STOCKHOLM, May 19, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on melflufen (INN melphalan flufenamide) in relapsed refractory multiple myeloma, RRMM, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators.

United statesRolf gulliksenKlaas bakkerLinda holmstrAmerican society of clinical oncologyGlobal head of corporate communicationsAmerican hematology associationNasdaq stockholmClinical oncologyExecutive vice presidentChief medical officerGlobal headCorporate communicationsInvestor relationsMid capRaiser oncopeptides release

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRolf gulliksenKlaas bakkerLinda holmstrAmerican society of clinical oncologyGlobal head of corporate communicationsAmerican hematology associationNasdaq stockholmClinical oncologyExecutive vice presidentChief medical officerGlobal headCorporate communicationsInvestor relationsMid capRaiser oncopeptides release